Pituitary adenylate cyclase-activating polypeptide ameliorates vascular dysfunction induced by hyperglycaemia

Area of Science:

• Endocrinology
• Vascular Biology
• Diabetes Research

Background:

• Short-lasting hyperglycemia frequently causes vascular damage in prediabetes and poorly controlled diabetes.
• Pituitary adenylate cyclase-activating polypeptide (PACAP) shows protective effects in diabetes-related vascular complications and possesses antioxidant properties.

Purpose of the Study:

• To investigate the protective effects of PACAP against short-term hyperglycemia-induced vascular dysfunction.

Main Methods:

• Vascular relaxation of mouse carotid arteries was assessed using a myograph after a 1-h hyperglycemic episode, with or without PACAP or superoxide dismutase.
• PACAP's direct antioxidant activity was tested via pyrogallol autoxidation assay.
• Hyperglycemia-associated vascular markers were measured to evaluate PACAP's effect.

Main Results:

• PACAP administration reduced endothelial dysfunction and restored acetylcholine-induced relaxation after hyperglycemia.
• PACAP improved sodium nitroprusside-induced relaxation, an effect similar to superoxide dismutase.
• PACAP decreased elevated levels of fibroblast growth factor basic, matrix metalloproteinase 9, and nephroblastoma overexpressed gene proteins associated with endothelial dysfunction.

Conclusions:

• PACAP demonstrates a significant protective role in mitigating vascular complications arising from diabetes.
• PACAP's mechanism involves improving endothelial function and reducing specific protein markers, rather than direct superoxide scavenging.